We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+13.04%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$587M
AUM Growth
-$222M
Cap. Flow
-$5.15B
Cap. Flow %
-877.82%
Top 10 Hldgs %
35.65%
Holding
170
New
43
Increased
23
Reduced
46
Closed
45

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$19.7M
2
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$16.8M
3
BIIB icon
Biogen
BIIB
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$8.46M
5
ORA icon
Ormat Technologies
ORA
+$7.92M

Top Sells

Rank Stock Value
1
ISRL
Isramco Inc
ISRL
+$4.99B
2
MRK icon
Merck
MRK
+$24.8M
3
ABBV icon
AbbVie
ABBV
+$23.3M
4
AGN
Allergan Inc
AGN
+$23M
5
JNJ icon
Johnson & Johnson
JNJ
+$22.1M

Sector Composition

Rank Sector Weight
1 Healthcare 63.04%
2 Technology 5.1%
3 Industrials 3.71%
4 Energy 1.9%
5 Consumer Discretionary 1.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
26
PTC Therapeutics
PTCT
$5.64B
$5.7M 0.97%
110,000
+46,375
+73% +$2.04M
VTRS icon
27
Viatris
VTRS
$20.4B
$5.47M 0.93%
97,100
– –
AMAG
28
DELISTED
AMAG Pharmaceuticals
AMAG
$5.34M 0.91%
125,230
-25,000
-17% -$903K
MDVN
29
DELISTED
MEDIVATION, INC.
MDVN
$5.29M 0.9%
106,230
-20,000
-16% -$1.04M
VNDA icon
30
Vanda Pharmaceuticals
VNDA
$307M
$5.28M 0.9%
368,390
+150,000
+69% +$1.77M
XLF icon
31
State Street Financial Select Sector SPDR ETF
XLF
$56.7B
$5.19M 0.88%
+239,221
New +$5.01M
TW
32
DELISTED
TOWERS WATSON & CO COM STK CL A (DE)
TW
$4.79M 0.82%
42,350
+14,350
+51% +$1.58M
TJX icon
33
TJX Companies
TJX
$174B
$4.64M 0.79%
135,260
+80,060
+145% +$2.55M
ARRY
34
DELISTED
Array Biopharma Inc
ARRY
$4.61M 0.78%
973,922
+100,000
+11% +$396K
CLVS
35
DELISTED
Clovis Oncology, Inc.
CLVS
$4.59M 0.78%
81,955
-20,000
-20% -$1.05M
FOLD
36
DELISTED
Amicus Therapeutics
FOLD
$4.58M 0.78%
+550,000
New +$3.77M
DYAX
37
DELISTED
DYAX CORPORATION
DYAX
$4.46M 0.76%
317,556
-200,000
-39% -$2.5M
GSK icon
38
GSK
GSK
$104B
$4.2M 0.72%
78,560
+880
+1% +$49.2K
FWP
39
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$4.17M 0.71%
+28,571
New +$4.12M
ORBK
40
DELISTED
Orbotech Ltd
ORBK
$4.16M 0.71%
280,872
-290,660
-51% -$4.34M
GILD icon
41
CALL
Gilead Sciences
GILD
$162B
$3.95M 0.67%
394,200
+200,000
+103% +$20.7M
CYTK icon
42
Cytokinetics
CYTK
$10.5B
$3.95M 0.67%
493,212
+130,000
+36% +$558K
RLYP
43
DELISTED
RELYPSA INC COM
RLYP
$3.92M 0.67%
127,100
+30,000
+31% +$714K
BRCM
44
DELISTED
BROADCOM CORP CL-A
BRCM
$3.85M 0.66%
88,800
-10,560
-11% -$433K
PBYI icon
45
Puma Biotechnology
PBYI
$404M
$3.84M 0.65%
20,296
-10,000
-33% -$2.22M
CBAY
46
DELISTED
Cymabay Therapeutics
CBAY
$3.84M 0.65%
390,355
-100,000
-20% -$804K
ITRN icon
47
Ituran Location and Control
ITRN
$1.09B
$3.71M 0.63%
168,203
-62,912
-27% -$1.33M
RCPT
48
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$3.67M 0.63%
30,000
+5,000
+20% +$506K
VRTX icon
49
Vertex Pharmaceuticals
VRTX
$121B
$3.56M 0.61%
30,000
-120,000
-80% -$13.5M
CVS icon
50
CVS Health
CVS
$133B
$3.53M 0.6%
36,610
-3,200
-8% -$282K
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sphera Funds Management held 170 positions worth $587M, down 27% from $809M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Sphera Funds Management withdrew a net $5.15B in Q4 2014, closing 45 positions and reducing 46 holdings. Its most notable exit was Merck, an estimated $24.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 57% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in Gilead Sciences worth $17.9M.

  • Sphera Funds Management's largest Q4 2014 buy was Gilead Sciences: 190,000 shares worth $17.9M.
  • Sphera Funds Management added most to SALIX PHARMACEUTICALS LTD DEL in Q4 2014, an estimated $16.8M increase.
  • Sphera Funds Management's biggest Q4 2014 reduction was Isramco Inc, cutting an estimated $4.99B.
  • Sphera Funds Management fully exited Merck in Q4 2014, selling an estimated $24.8M.
  • Sphera Funds Management's ten largest holdings make up 36% of its $587M portfolio in Q4 2014.
  • Sphera Funds Management opened 43 new positions and closed 45 in Q4 2014.
  • Sphera Funds Management's portfolio value fell 27% quarter-over-quarter to $587M.

Based on Sphera Funds Management's 13F filing for Q4 2014, filed 12 Feb 2015.